Aspirin, a low-cost over-the-counter drug, will be seen as a viable treatment for hospitalized patients with COVID-19 in the world’s largest study of a range of potential treatments for this disease.
Patients infected with coronavirus have a high risk of forming blood clots in the blood vessels due to strong platelets – small fragments of cells in the blood that stop the bleeding,
Since aspirin is an anti-platelet aggregation agent, it may reduce the risk of blood clots in patients with COVID-19, a Random Review of the COVid-19 THERapY (RESTORE) trial says on its website. me on Friday.
“There is a clear reason to believe it can be beneficial and that it is safe, inexpensive and widely available,” said Professor Peter Horby from the Nuffield Department of Medicine and co-lead investigator of the RECOVERY trial, know.
“We are looking for drugs for COVID-19 that can be used immediately for anyone, anywhere in the world. We don’t know if aspirin is such a medicine but we’ll find out, ”Horby added.
Read: Does ibuprofen make coronavirus worse? Is it still safe to take aspirin?
Trials are taking place in 176 hospitals across the UK, and so far have enrolled more than 16,000 patients.
At least 2,000 patients will be randomly assigned to receive 150 mg of aspirin per day and the results will be compared with at least 2,000 patients receiving their own standardized care, RECOVERY said.
Read: Regeneron inflated his third quarter earnings estimate and said he shared COVID-19 vaccine data with FDA
Other treatments being tested in the trial include the popular antibiotics azithromycin and REGN-COV2, a cocktail of antiviral antibodies made by Regeneron REGN,
used to treat COVID-19 symptoms by US President Donald Trump.
Researchers around the world are testing a combination of existing therapies as well as new experimental drugs to find the best treatment for COVID-19 infection.
Aspirin is widely used to prevent blood clots associated with many other medical conditions, including heart attack, stroke and pre-eclampsia in pregnant women.
Researchers at the University of Maryland Medical School (UMSOM) found that COVID-19 hospitalized patients taking low-dose aspirin daily to protect against cardiovascular disease had a lower risk of complications and death. significantly compared to those not taking aspirin. .
The study, published October 21 in the journal Anesthesia and Analgesia, looked at the medical records of 412 Covid-19 patients treated at the University of Maryland Medical Center in Baltimore and three other hospitals along the line. East Coast.
Research shows that aspirin users are less likely to be admitted to an intensive care unit or to have a mechanical ventilator, and they are more likely to survive an infection than in hospitalized patients who are not taking. aspirin.
The decision to add aspirin to the RESTORE test was made by Oxford University researchers, who led the trial in conjunction with the medical director, as recommended by UK Therapy Advisory Council COVID-19.